AstraZeneca announced its intention to establish a new global R&D centre and corporate headquarters in Cambridge in the UK by 2016.

View our full UK press release
 

Under the plans, AstraZeneca’s small molecule and biologics R&D activities will be concentrated in three strategic centres: Cambridge; Gaithersburg, US; and Mölndal, Sweden.

For more information please visit our global website, astrazeneca.com.

Read more